Clinical trial PRISM-1
A Randomized, Placebo-Controlled, Double-Blind, Multicenter Phase 3 Trial of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma Not Previously Treated in the Metastatic Setting
| Cancers | |
|---|---|
| Organ | pancreas |
| Trial status | Trial open for recruitment |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 3 |
| Academic trial | Non |
| Sponsor | Arcus Biosciences, Inc. |
| EudraCT Identifier | 2024-513317-12-00 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT06608927 |
| Last update |